Population-, intervention- and methodology-related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for breast cancer: a meta-regression analysis

2014 ◽  
Vol 24 (7) ◽  
pp. 737-747 ◽  
Author(s):  
Marion Carayol ◽  
Cyrille Delpierre ◽  
Paquito Bernard ◽  
Grégory Ninot
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Regression Analysis ◽  
Adjuvant Therapy ◽  
Impact Exercise ◽  
Meta Regression ◽  
Meta Regression Analysis

Is pancreaticogastrostomy safer than pancreaticojejunostomy after pancreaticoduodenectomy? A meta-regression analysis of randomized clinical trials

Pancreatology ◽  
2017 ◽  
Vol 17 (5) ◽  
pp. 805-813 ◽  
Author(s):  
Claudio Ricci ◽  
Riccardo Casadei ◽  
Giovanni Taffurelli ◽  
Carlo Alberto Pacilio ◽  
Denis Beltrami ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Regression Analysis ◽  
Randomized Clinical Trials ◽  
Meta Regression ◽  
Meta Regression Analysis

Magnitude of benefit of the addition of bevacizumab (BEVA) to first-line chemotherapy (CT) for advanced/metastatic colorectal cancer (MCRC): Meta-analysis of randomized clinical trials

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15021-e15021
Author(s):  
V. Vaccaro ◽  
F. Cuppone ◽  
F. Loupakis ◽  
M. Milella ◽  
P. Carlini ◽  
...  
Keyword(s):  
Sensitivity Analysis ◽  
Clinical Trials ◽  
Regression Analysis ◽  
Phase Ii ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Phase Iii ◽  
Phase Ii Trials ◽  
Meta Regression ◽  
Meta Regression Analysis

e15021 Background: The monoclonal antibody against vascular endothelial growth factor BEVA has recently demonstrated to improve survival for MRC patients (pts). Nevertheless, the magnitude of the provided benefit in the daily practice is still controversial. In order to quantify the benefit of adding BEVA to CT for MCRC, a literature-based meta-analysis was conducted. Methods: Survival Hazard Ratios (HR) were extracted from prospective, randomized clinical trials (RCTs, either phase II/III) reports. HR and event-based relative risks (RR) with 95% confidence intervals (CI) were derived through a random-effect model. Differences in primary (progression-free- and overall-survival, PFS/OS) and secondary outcomes (overall, partial and complete response rates, ORR/PR/CR) were explored. Absolute differences (AD) and the number of patients needed to treat (NNT) were calculated. Heterogeneity test and a meta-regression analysis with clinical predictors for outcomes were conducted as well. A sensitivity analysis according to the trial phase-design was accomplished. Results: Five trials (2,728 pts), 2 phase II (313 pts) and 3 phase III (2,415 pts), were gathered. No significant interaction was found in the sensitivity analysis between phase II and III, although a trend showed a better PFS results for BEVA in phase II trials (p=0.057). At the meta-regression analysis female gender and rectal primary site were significant predictors for PFS (p=0.003, p=0.005). Toxicity analysis is ongoing. Conclusions: Although concerns regarding costs and toxicities still exist, BEVA significantly improves the outcome of untreated MCRC pts. The absolute benefit provided into an unselected population for molecular features should be considered of paramount importance for advanced disease. [Table: see text] No significant financial relationships to disclose.

Is pancreaticogastrostomy safer than pancreaticojejunostomy after pancreaticoduodenectomy? A meta-regression analysis of randomized clinical trials

Pancreatology ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. S80
Author(s):  
Giovanni Taffurelli ◽  
Claudio Ricci ◽  
Carlo Alberto Pacilio ◽  
Denis Beltrami ◽  
Francesco Minni ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Regression Analysis ◽  
Randomized Clinical Trials ◽  
Meta Regression ◽  
Meta Regression Analysis
Sign in / Sign up

Export Citation Format

Share Document